Search Results - "DePaolo, Dawn"

A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors by Ngamphaiboon, Nuttapong, Dy, Grace K., Ma, Wen Wee, Zhao, Yujie, Reungwetwattana, Thanyanan, DePaolo, Dawn, Ding, Yi, Brady, William, Fetterly, Gerald, Adjei, Alex A.

“…Based on preclinical data demonstrating cytotoxic synergy between sorafenib and entinostat, a phase I study of this combination was conducted in patients with…”
Get full text

Evaluation of Quality-of-life (QoL) in patients(pts) with advanced solid tumors as screening tool during phase 1 clinical trial recruitment- risk assessment for adverse events and subject replacement by Anwar, Sidra, Tan, Wei, Hong, Chi-Chen, Admane, Sonal, Dozier, Askia, Siedlecki, Francine, Whitworth, Amy, DiRaddo, Ann Marie, DePaolo, Dawn, Jacob, Sandra M, Ma, Wen Wee, Miller, Austin, Adjei, Alex A., Dy, Grace K.

“…Abstract only…”
Get full text

Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events by Anwar, Sidra, Tan, Wei, Hong, Chi-Chen, Admane, Sonal, Dozier, Askia, Siedlecki, Francine, Whitworth, Amy, DiRaddo, Ann Marie, DePaolo, Dawn, Jacob, Sandra M, Ma, Wen Wee, Miller, Austin, Adjei, Alex A, Dy, Grace K

“…: Serious adverse events (SAEs) and subject replacements occur frequently in phase 1 oncology clinical trials. Whether baseline quality-of-life (QOL) or social…”
Get full text

Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma by Chanan-Khan, Asher Alban, Gharibo, Mecide, Jagannath, Sundar, Munshi, Nikhil C., Anderson, Kenneth C, DePaolo, Dawn, Lee, Kelvin P., Miller, Kena, Guild, Robin, Zildjian, Sybil, Qin, Albert

“…Background: IMGN901 (huN901-DM1) is a novel conjugate of the cytotoxic maytansinoid, DM1, with the humanized CD56-binding monoclonal antibody, N901. Once bound…”
Get full text

Renal Dysfunction Does Not Affect Clinical Response in Multiple Myeloma (MM) Patients Treated with Bortezomib-Based Regimens by Ailawadhi, Sikander, Mashtare, Terry L., Coignet, Marie V., Depaolo, Dawn M., Miller, Kena C., Wilding, Gregory, Chanan-Khan, Asher Alban

“…Background: Renal dysfunction is a common consequence of MM. Patients can present with varying degrees of renal impairment during the course of their disease…”
Get full text

Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT) for the Treatment of Previously Untreated Multiple Myeloma by Chanan-Khan, Asher A., Miller, Kena C., DePaolo, Dawn, Padmanabhan, Swaminathan, Whitworth, Amy, Ailawadhi, Sikander, Lee, Kelvin, Czuczman, Myron S.

“…Introduction: Orlowski et al were the first to report that addition of PLD resulted in enhanced efficacy of bortezomib. To further optimize the clinical…”
Get full text

Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism by Miller, Kena C., Padmanabhan, Swaminathan, Dimicelli, Laurie, Depaolo, Dawn, Landrigan, Beverly, Yu, Jihnhee, Doran, Virginia, Marshal, Patricia, Chanan-Khan, Asher

“…Venous thromboemobolism (VTE) is an important complication of thalidomide therapy especially when it is combined with steroids or chemotherapy. Currently there…”
Get full text

Lenalidomide Associated Tumor Flare Reaction Correlates with Clinical Response in Patients with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia by Sher, Taimur, Patel, Mehul, Whitworth, Amy, Miller, Kena, Musial, Laurie, Lawrence, David, Padmanabhan, Swaminathan, Ailawadhi, Sikander, Wilding, Gregory, DePaolo, Dawn, Bangia, Naveen, Czuczman, Myron S., Wallace, Paul K., Lee, Kelvin P., Khan, Asher Chanan

“…INTRODUCTION: We have previously reported that in patients with B-CLL, lenalidomide induces a tumor flare reaction (TFR) that is clinically characterized by…”
Get full text

Phase I Study of huN901-DM1 (BB-10901) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma by Chanan-Khan, Asher A., Jagannath, Sundar, Munshi, Nikhil C., Schlossman, Robert L., Anderson, Kenneth C., Lee, Kelvin, DePaolo, Dawn, Miller, Kena C., Zildjian, Sybil, Fram, Robert J., Qin

“…Background: huN901-DM1 (BB-10901) is a humanized monoclonal antibody that binds with high affinity to CD56 and is covalently linked to a novel cytotoxic…”
Get full text

Oral Acyclovir Is an Effective in Decreasing the Incidence of Bortezomib Associated Herpes Zoster in Patients with Multiple Myeloma by DePaolo, Dawn, Miller, Kena C., Whitworth, Amy, Mohr, Alice, Mashtare, Terry L., Wilding, Gregory, Ailawadhi, Sikander, Padmanabhan, Swaminathan, Chanan-Khan, Asher A.

“…Introduction: Bortezomib, a proteasome inhibitor is an effective antimyeloma therapy. We recently reported that multiple myeloma patients treated with…”
Get full text

bcl-2 Translocation [t(14;18) (q32;q21)] Does Not Correlate with Poor Clinical Outcome in Multiple Myeloma Patients Treated with Bortezomib by Ailawadhi, Sikander, Mashtare, Terry L., Coignet, Marie V., DePaolo, Dawn M., Miller, Kena C., Padmanabhan, Swaminathan, Wilding, Gregory, Starostik, Petr, Chanan-Khan, Asher A.

“…Background: Overexpression of bcl-2 gene mediated by t(14;18) (q32;q21) results in increased transcription of the anti-apoptotic bcl-2 protein. This is…”
Get full text

Incidence, Clinical Presentation and Outcome of Secondary Multiple Extramedullary Plasmacytomas: Experience at Roswell Park Cancer Institute by Manochakian, Rami, Miller, Kena C., Coignet, Jean-Gabriel, Padmanabhan, Swami, Musial, Laurie, DePaolo, Dawn, Chanan-Khan, Asher Alban

“…Introduction: Extramedullary plasmacytomas are malignant plasma cell tumors that arise outside of the bone marrow. They occur either as solitary tumors with a…”
Get full text

Weight Adjusted Low-Dose Warfarin Decreases the Incidence of Thalidomide (T) Associated Venous Thromboembolism (VTE) in Patients (pts) with Multiple Myeloma (MM) and Waldenstroms Macroglobulinemia (WM) by Miller, Kena C., Manochakian, Rami, Padmanabhan, Swaminathan, Coignet, Jean-Gabriel, Musial, Laurie, DePaolo, Dawn, Chanan-Khan, Asher Alban

“…Introduction: T is an effective antimyeloma therapy. An important and problematic side effect of T is development of VTE. The underlying etiology of T…”
Get full text

Low-Dose Prednisone Decreases the Severity but Not the Frequency of Lenalidomide Associated Tumor Flare Feaction (TFR) in Chronic Lymphocytic Leukemia (CLL) Patients by Musial, Laurie, Miller, Kena C., Tonelli, Amy, Manochakian, Rami, Padmanabhan, Swaminathan, Lawrence, David, DePaolo, Dawn, Coignet, Jean-Gabriel, Chanan-Khan, Asher Alban

“…Introduction: Lenalidomide (L) is clinically active in pts with CLL. TFR is a common side effect of L, unique to CLL pts and is characterized by tender…”
Get full text

Phase I Study of BB-10901 (huN901-DM1) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma by Chanan-Khan, Asher Alban, Jagannath, Sundar, Schlossman, Robert L., Fram, Robert J., Falzone, Richard M., Ruberti, Mary F., Welch, Samantha K., DePaolo, Dawn, Anderson, Kenneth C., Munshi, Nikhil C.

“…Background: BB-10901 is a humanized monoclonal antibody that binds with high affinity to CD56 and is covalently linked to a novel cytotoxic maytansinoid DM1…”
Get full text

Characterization of IMiDs (Immunomodulating Agents) Induced “Flare Reaction” in Patients with Chronic Lymphocytic Leukemia (CLL) and Correlation with Changes in Serum Cytokine Levels by DiMiceli, Laurie, Miller, Kena C., Rickert, Michael, Wallace, Paul, Marshall, Patricia, DePaolo, Dawn, Padmanabhan, Swaminathan, Landrigan, Beverly, Chanan-Khan, Asher A.

“…Introduction: Several cytokines (including TNF-alpha, IL-6 and VEGF) are reported to play a critical role in the pathogenesis of CLL cells. Targeting the tumor…”
Get full text